Cerus Corporation (Nasdaq: CERS) announced today its schedule of key events and presentations at the 2018 AABB Annual Meeting which is taking place in Boston on October 13 through October 16.
The AABB Annual Meeting is the largest blood banking conference of the year. Scientists and clinicians from around the world will be attending to learn about the latest developments in the industry.
Scheduled presentations of interest include the economic impact of implementing pathogen-reduced platelets at blood centers and hospitals, additional data reinforcing the clinical utility of pathogen-reduced platelets, and results from SPARC, Cerus European Phase 3 study of pathogen-reduced red blood cells.
We are pleased to share with the blood banking community the latest data on the INTERCEPT Blood System, which further adds to the clinical body of evidence supporting the use of pathogen-reduction to improve the safety and availability of the blood supply, said Dr. Richard Benjamin, Cerus chief medical officer.
This year, we have 7 oral presentations that we think underscore the growing interest in pathogen-reduction and increasing awareness on the risks associated with transfusion transmitted infections, continued Benjamin. Between Cerus and our scientific collaborators, we will have 22 abstract presentations at AABB.
Company representatives from Cerus will be in the exhibition areas at booth #2133.
The following is a select list of presentations of interest. All presentations are listed in Eastern Daylight Time (EDT). A full list of Cerus related abstracts can be viewed at https://intercept-usa.com/aabb2018.
Saturday, October 13, 2018
10:00 am “ 11:30 am: ST2-15: Neonatal and Pediatric Platelet Transfusion “ Unresolved Clinical Issues; Convention Center “ 253C, Session will include a presentation on the incidences of transfusion reactions following transfusion of conventional and pathogen-reduced platelets.
Sunday, October 14, 2018
1:00 pm “ 2:00 pm: MGT4: Platelet Availability and Economic Impact of Bacterial Risk Reduction Strategies at US Blood Centers; Convention Center “ Hall A
1:00 pm “ 2:00 pm: BBC104: Complete Inactivation of Mers-Coronavirus in Human Apheresis Platelets with Amotosalen and Ultraviolet a Light Treatment; Convention Center “ Hall A
4:00 pm “ 5:30 pm: SN5-40: Pediatric Transfusion Medicine: Whats Hot and New? (Mobile ARS); Convention Center “ 157, Session will include a presentation on the use of pathogen-reduced blood components in pediatric patients.
Monday, October 15, 2018
7:00 am “ 8:15 am: Cerus Industry Workshop, The Role of Pathogen Reduction in Reversing Blood Component Commoditization; Convention Center “ 252AB
8:30 am “ 10:00 am: MN1-8: Bacterial Mitigation Strategies for Platelet Concentrates: The Transfusion Service Perspective; Convention Center “ 157. Session will include a presentation discussing the impact of implementing pathogen reduction on utilization, transfusion reactions, and hospital finances.
2:15 pm “ 2:30 pm: TS25-MN3-22: Transfusion of Pathogen Reduced Vs. Conventional Platelets in Pediatric Patients: An Assessment of Platelet Usage and Incidence of Transfusion Reactions; Convention Center “ 151
4:30 pm “ 4:45 pm: NIT3-MN4-35: Amustaline/Glutathione Pathogen-Inactivated RBC in Thalassemia: A Randomized, Controlled, Phase III Study (SPARC); Convention Center “ 205C
4:45 pm “ 5:00 pm: BBC4-MN4-33: Simultaneous Inactivation of Co-Circulating Arboviruses through Nucleic Acid Crosslinking; Convention Center – 151AB
5:00 pm “ 5:15 pm: BBC15-MN4-33: Optimization of Pathogen Reduction Compatibility at 13 Blood Centers; Convention Center – 151
Tuesday, October 16, 2018
11:15 am “ 11:30am: MGT3-TU3-23: Platelet Availability and Economic Impact of Bacterial Risk Reduction Strategies at US Hospitals; Convention Center “ 151
Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. See http://www.cerus.com for information about Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
Tim Lee, 925-288-6137